Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Neonatal fc receptor blockers
8 evidence topics · 5 sources
FDA-approved neonatal Fc receptor blocker for CIDP: indication and dosing
Subcutaneous efgartigimod randomized withdrawal trial: response and relapse
“Participants with evidence of clinically meaningful deterioration entered an open-label phase of weekly 1000 mg subcutaneous efgartigimod PH20 for no longer than 12 weeks (stage A).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between April 15, 2020, and May 11, 2023, 629 participants were screened; 322 (114 female, 208 male) entered stage A, of whom 214 (66%, 95% CI 61·0-71·6) had confirmed ECI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subcutaneous efgartigimod PH20 significantly reduced the risk of relapse versus placebo (hazard ratio 0·39 [95% CI 0·25-0·61]; p<0·0001). 31 (27·9% [19·6-36·3]) participants given subcutaneous efgartigimod PH20 had a relapse versus 59 (53·6% [44·3-63·0]) given placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In stage B, TEAEs occurred in 71 (64%) participants on subcutaneous efgartigimod PH20 and 62 (56%) participants on placebo, and serious TEAEs in six (5%) on subcutaneous efgartigimod PH20 and six (5%) on placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: long-term safety and function
“At interim data cut‐off (February 16, 2024), 228/229 eligible participants advanced to ADHERE+.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prolonged efgartigimod exposure did not increase the incidence ( n = 171/228 [75.0%]) or severity of TEAEs (grade ≥ 3 TEAEs, n = 41/228 [18.0%]); regardless of immunoglobulin G level, there was a low incidence of infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stage A responders reported long‐term clinically meaningful improvements in mean aINCAT (decreased by 1.2 points), I‐RODS centile metric (increase of 8.8 points), and GS scores (increase of 17.5 kPa) from run‐in baseline to ADHERE+ week 36, irrespective of stage B treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous efgartigimod randomized withdrawal trial: registry participant flow
Subcutaneous efgartigimod randomized withdrawal trial: registry results for stage B time-to-event and disability outcomes
| Stage B outcome | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Median time to first adjusted INCAT deterioration, days (95% CI) | “NA[1] (NA to NA)” | “140.0[2] (75.0 to NA)” |
| Median time to CIDP disease progression, days (95% CI) | “NA[1] (247.0 to NA)” | “85 (50.0 to 253.0)” |
| Mean (SD) change in adjusted INCAT score from stage B baseline | “0.1(1.08)” | “0.9(1.98)” |
Subcutaneous efgartigimod randomized withdrawal trial: registry definitions for stage B outcomes
Subcutaneous efgartigimod randomized withdrawal trial: registry all-cause mortality and serious adverse events
| Event | Stage A efgartigimod PH20 SC | Stage B efgartigimod PH20 SC | Stage B placebo PH20 SC |
|---|---|---|---|
| All-cause mortality, affected/at risk (%) | “2/322 (0.62%)” | “0/111 (0.00%)” | “1/110 (0.91%)” |
| Serious adverse events, affected/at risk (%) | “21/322 (6.52%)” | “6/111 (5.41%)” | “6/110 (5.45%)” |